참고문헌 (48)

1. Mol Cell Biol CV Dang 19 1 1999 10.1128/MCB.19.1.1 Dang CV (1999) C-myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol 19:1-11 

   상세보기

2. EMBO Rep D Cappellen 8 70 2007 10.1038/sj.embor.7400849 Cappellen D, Schlange T, Bauer M, Maurer M, Hynes NE (2007) Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8:70-76 

   상세보기

3. Biochim Biophys Acta W Lutz 602 61 2002 Lutz W, Leon J, Eilers M (2002) Contributions of Myc to tumorigenesis. Biochim Biophys Acta 1602:61-71 

4. Endocr Relat Cancer DJ Liao 7 143 2000 10.1677/erc.0.0070143 Liao DJ, Dickson RB (2000) C-myc in breast cancer. Endocr Relat Cancer 7:143-164 

   상세보기

5. J Steroid Biochem Mol Biol EM Berns 43 13 1992 10.1016/0960-0760(92)90182-I Berns EM, Foekens JA, van Putten WL, van Staveren IL, Portengen H, de Koning WC, Klijn JG (1992) Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol 43:13-19 

   상세보기

6. Eur J Cancer EM Berns 28 697 1992 10.1016/S0959-8049(05)80129-7 Berns EM, Kiijn JG, van Starveren IL, Portengen H, de Koning WC, Foekens JA (1992) Prevalence of amplification of the oncogene c-myc, HER2/neu, and int-2 in one thousand human breast tumors: correlation with steroid receptor status. Eur J Cancer 28:697-700 

   상세보기

7. Br J Cancer A Scorilas 81 1385 1999 10.1038/sj.bjc.6693404 Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M (1999) Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer 81:1385-1391 

   상세보기

8. Mod Pathol JK Rummukainen 14 1030 2001 10.1038/modpathol.3880431 Rummukainen JK, Salminen T, Lundin J, Kytölä S, Joensuu H, Isola JJ (2001) Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 14:1030-1035 

   상세보기

9. Curr Cancer Drug Targets H Hermeking 3 163 2003 10.2174/1568009033481949 Hermeking H (2003) The Myc oncogene as a cancer drug target. Curr Cancer Drug Targets 3:163-175 

   상세보기

10. Exp Mol Pathol N Todorović-Raković 82 262 2007 10.1016/j.yexmp.2007.01.002 Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D (2007) Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer. Exp Mol Pathol 82:262-268 

    상세보기

11. Dis Markers N Todorović-Raković 26 171 2009 10.1155/2009/808947 Todorović-Raković N, Nesković-Konstantinović Z, Nikolić-Vukosavljević D (2009) Metastatic breast cancer survival according to HER2 and Topo2a gene status. Dis Markers 26:171-180 

    상세보기

12. PNAS C Escot 83 4834 1986 10.1073/pnas.83.13.4834 Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. PNAS 83:4834-4838 

    상세보기

13. J Natl Cancer Inst M Bonilla 80 665 1988 10.1093/jnci/80.9.665 Bonilla M, Ramirez M, Lopez-Cueto J, Gariglio P (1988) In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80:665-671 

    상세보기

14. Cancer Y Harada 74 2281 1994 10.1002/1097-0142(19941015)74:8<2281::AID-CNCR2820740812>3.0.CO;2-I Harada Y, Katagiri T, Ito I, Sakamoto G, Kasumi F, Nakamura Y, Emi M (1994) Genetic studies of 457 breast cancers. Clinocopathological parameters compared with genetic alterations. Cancer 74:2281-2286 

    상세보기

15. Int J Cancer A Contegiacomo 61 1 1995 10.1002/ijc.2910610102 Contegiacomo A, Pizzi C, De Marchis L, Alimandi M, Delrio P, Di Palma E et al (1995) High cell kinetics is associated with amplification of the int-1, bcl1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancer. Int J Cancer 61:1-6 

    상세보기

16. Br J Cancer I Ito 71 438 1995 10.1038/bjc.1995.89 Ito I, Yoshimoto M, Iwase T, Watanabe H, Katagiri T, Harada Y et al (1995) Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br J Cancer 71:438-441 

    상세보기

17. Oncogene J Adnane 4 1389 1989 Adnane J, Gaudray P, Simon MP, Simony-Lafontaine J, Jeanteur P, Theillet C (1989) Proto-oncogene amplification and human breast cancer phenotype. Oncogene 4:1389-1395 

    상세보기

18. Anticancer Res Y Mizukami 11 1485 1991 Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y et al (1991) Immunohistochemical study of oncogene product ras 21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res 11:1485-1494 

    상세보기

19. Cancer Res F Courjal 57 4368 1997 Courjal F, Theillet C (1997) Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 57:4368-4377 

    상세보기

20. Cancer Res M Cuny 60 1077 2000 Cuny M, Kramer A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H et al (2000) Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60:1077-1083 

    상세보기

21. Mod Pathol DL Persons 10 720 1997 Persons DL, Borelli KA, Hsu PH (1997) Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescent in situ hybridization. Mod Pathol 10:720-727 

    상세보기

22. Cancer Res H Kreipe 53 1956 1993 Kreipe H, Feist H, Fischer L, Feigner J, Heidorn K, Mettler L, Parwarech R (1993) Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53:1956-1961 

    상세보기

23. Br J Cancer SL Deming 83 12 1688 2000 10.1054/bjoc.2000.1522 Deming SL, Nass SJ, Dickson RB, Trock JB (2000) C-myc amplification in breast cancer: a meta analysis of its occurrence and prognostic relevance. Br J Cancer 83(12):1688-1695 

    상세보기

24. Mol Endocrinol C Wang 25 1527 2011 10.1210/me.2011-1037 Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH (2011) Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 25:1527-1538 

    상세보기

25. Breast Cancer Res Y Wang 7 R220 2005 10.1186/bcr975 Wang Y, Liu S, Zhang G, Zhou C, Zhu H, Zhou X et al (2005) Knockdown of c-myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 7:R220-R228 

    상세보기

26. J Biol Chem D Dubik 263 12705 1988 10.1016/S0021-9258(18)37810-4 Dubik D, Shiu RP (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263:12705-12708 

    상세보기

27. Genes Dev PL Bernstein 6 642 1992 10.1101/gad.6.4.642 Bernstein PL, Herrick DJ, Prokipcak RD, Ross J (1992) Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant. Genes Dev 6:642-654 

    상세보기

28. J Steroid Biochem Mol Biol MSJ Wong 39 39 1991 10.1016/0960-0760(91)90010-3 Wong MSJ, Murphy LC (1991) Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 39:39-44 

    상세보기

29. Mol Cell Biol EA Musgrove 11 10 5032 1991 10.1128/MCB.11.10.5032 Musgrove EA, Lee CS, Sutherland RL (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11(10):5032-5043 

    상세보기

30. J Pathol EC Robarius-Mandag 201 75 2003 10.1002/path.1385 Robarius-Mandag EC, Bosch CA, Kristel PM, Hart AAM, Farieyte IF, Nederlof PM et al (2003) Association of c/myc amplification with progression from the in situ to the invasive stage in c-myc amplified breast carcinomas. J Pathol 201:75-82 

    상세보기

31. J Clin Pathol SM Rodriguez-Pinilla 60 1017 2007 10.1136/jcp.2006.043869 Rodriguez-Pinilla SM, Jones RL, Lambros MBK, Arriola E, Savage K, James M et al (2007) MYC amplification in breast cancer: a chromogenic in situ hybridization study. J Clin Pathol 60:1017-1023 

    상세보기

32. J Clin Pathol S Aulmann 59 424 2006 10.1136/jcp.2005.029264 Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP (2006) C-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol 59:424-428 

    상세보기

33. PNAS A Wolfer 107 3698 2009 10.1073/pnas.0914203107 Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN et al (2009) MYC regulation of a “poor-prognosis” metastatic cancer cell state. PNAS 107:3698-3703 

    상세보기

34. Int J Cancer A Borg 51 687 1992 10.1002/ijc.2910510504 Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H (1992) C-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 51:687-691 

    상세보기

35. Eur J Cancer M Roux-Dosseto 2 1600 1992 10.1016/0959-8049(92)90050-C Roux-Dosseto M, Romain S, Dissault N, Desiders C, Piana L, Bonnier P et al (1992) C-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer 2:1600-1604 

    상세보기

36. Oncogene Res M Guerin 3 21 1988 Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G (1988) Overexpression of either c-myc or c-erbB2 protooncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 3:21-31 

    상세보기

37. Int J Oncol K Mimori 12 597 1998 Mimori K, Mori M, Shiraishi T, Tanaka S, Haraguchi M, Ueo H et al (1998) Expression of ornithine decarboxylase mRNA and c-myc mRNA in breast tumors. Int J Oncol 12:597-601 

    상세보기

38. Anticancer Res Y Mizukami 11 1485 1991 Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y et al (1991) Immunohistochemical study of oncogene product ras 21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res 11:1485-1494 

    상세보기

39. Int J Cancer M Gutman 44 802 1989 10.1002/ijc.2910440509 Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shifon Y (1989) Amplification of c-myc and c-erbB2 proto-oncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 44:802-805 

    상세보기

40. Cancer Res I Bieche 59 2759 1999 Bieche I, Laurendau I, Tozlu S, Olivi M, Vidaud D, Lidereau R et al (1999) Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59:2759-2765 

    상세보기

41. Anticancer Res T Pietilainen 15 959 1995 Pietilainen T, Lipponen P, Aaltuman S, Eskelinen M, Kosma VM, Syrjanen K (1995) Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 15:959-964 

    상세보기

42. Eur J Cancer H Yasojima 12 1779 2011 10.1016/j.ejca.2011.06.017 Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K et al (2011) Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer 12:1779-1788 

    상세보기

43. Cancer Res LH Augenlicht 57 1769 1997 Augenlicht LH, Wadler S, Corner G, Richards C, Ryan I, Multani AS et al (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57:1769-1775 

    상세보기

44. Cancer Sci T Iba 95 418 2006 10.1111/j.1349-7006.2004.tb03225.x Iba T, Kigawa J, Kanantori Y, Itamochi H, Oishi T, Simada M et al (2006) Expression of the e c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 95:418-423 

    상세보기

45. Eur J Cancer JFR Robertson 33 1774 1997 10.1016/S0959-8049(97)00178-0 Robertson JFR, Willsher PC, Cheung KL et al (1997) The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774-1779 

    상세보기

46. Breast Cancer Res CM Schlotter 5 R30 2003 10.1186/bcr568 Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K (2003) C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 5:R30-R36 

    상세보기

47. Oncologist EF Petrelli 13 373 2008 10.1634/theoncologist.2007-0173 Petrelli EF, Cabiddu M, Cazzaniga ME et al (2008) Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 13:373-381 

    상세보기

48. Clin Cancer Res H Biliran 13 2811 2007 10.1158/1078-0432.CCR-06-1844 Biliran H, Banerjee S, Thakur A et al (2007) C-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-κB activity in pancreatic cancer cells. Clin Cancer Res 13:2811 

    상세보기